



DEKK-TEC, Inc.

Contact: Lee Roy Morgan, MD, PhD

Location: New Orleans, Louisiana

Email: lm1579@aol.com

Tel: (504) 583-6135



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health



National Institutes of Health Commercialization Assistance Program (NIH-CAP)

Company Profile

Industry Sector: Pharmaceuticals

Company Overview: DEKK-TEC was formed in 1983, and has utilized government and private funding to effectively develop new therapies and clinical development candidates for the treatment of cancer, pre-cancerous lesions, and women's health issues. We have previously partnered two of our pipeline products to Biotech/Pharmaceutical companies who have successfully driven these compounds into Phase II clinical development.

Our present objective is to continue to create and develop clinical stage investment/partnership opportunities based on our current novel cancer therapeutic agent DM-CHOC-PEN.

Target Market(s): -Oncology (CNS & metastatic tumors, solid tumors)

Management

Leadership:

- Lee Roy Morgan, MD, PhD - CEO

Organic chemist, pharmacologist, & medical oncologist

-Andrew Rodgers, PhD - Director of Research & Regulatory Affairs

Analytical chemist, FDA regulatory affairs

-Lisa Stokes-Hasten, BSRN – Clinical Research

Certified oncology nurse

-Leo Mensink, MBA - Director of European Affairs

EU financial specialist

Scientific Advisory Board:

-Lesley A. Meng, MD

Phase I Director, Arizona Cancer Institute, Scottsdale, AZ

Key Value Drivers

Technology*:

DM-CHOC-PEN – novel anti-cancer agent able to cross the blood brain barrier

Competitive Advantage: DM-CHOC-PEN is our proprietary investigational alkylating cancer agent with the specific advantage of being able to cross the blood brain barrier. Current brain cancer drugs do not cross the blood brain barrier so must be given intra-cranially where they cause significant toxicity and have shown only modest efficacy. DM-CHOC-PEN, which can be given intravenously because it crosses the blood brain barrier, has shown superior efficacy to available therapies in pre-clinical studies, as well as a favorable safety, toxicity and PK/PD profiles. As such, DM-CHOC-PEN represents a significant new cancer therapy opportunity to address a large unmet medical need.

Plan & Strategy: -Initiate a Phase I/II with IV DM-CHOC-PEN in patients with brain metastases refractory to the current standard of care.

Product Pipeline

Compound	IND	P1	P2	P3	NDA	Partner
A-007	HPV Related Cancers					
IPM (ZIO-201)	Sarcoma/Others					
Progesterone	Premenstrual Syndrome					
DM-CHOC-PEN	CNS Cancers/others					
Camptothecins	Cancer					
HOO-IFOS	Cancer					
Pyrroles	Cancer					